For NSCLC patients with brain metastases harbouring METex14 skipping mutations, the type Ib MET inhibitors tepotinib and capmatinib may be considered as reasonable therapeutic options in addition to other multidisciplinary approaches. The gene discussed is MET; the disease is non-small cell lung carcinoma.